Filing Flows › Veracyte (VCYT) › Capital expenditures
Veracyte (VCYT) capital expenditures by quarter
Veracyte's capital expenditures were $2.3M in Q3 2026 (third quarter 2026), -18% from Q2 2026. Over the last 7 quarters it ranged from $1.3M (Q2 2025) to $3.8M (Q4 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $2.3M | -18% | -16% |
| Q2 2026 | $2.9M | -3% | +122% |
| Q1 2026 | $3.0M | -22% | +63% |
| Q4 2025 | $3.8M | +35% | — |
| Q3 2025 | $2.8M | +117% | — |
| Q2 2025 | $1.3M | -29% | — |
| Q1 2025 | $1.8M | — | — |
Q3 2026 at a glance
Veracyte, Q3 2026: revenue $152M (+15% year over year), operating margin 10.9%, net earnings $31.5M, operating cash flow $40.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Veracyte's capital expenditures?
Veracyte's capital expenditures were $2.3M in Q3 2026 (third quarter 2026), -18% from Q2 2026.
How has Veracyte's capital expenditures changed?
Over the last 7 quarters it ranged from $1.3M (Q2 2025) to $3.8M (Q4 2025).